Tech Company Financing Transactions
Lynk Pharmaceuticals Funding Round
On 6/1/2023, Lynk Pharmaceuticals secured $28.2 million in Series C funding from China Grand Prosperity Investment, Liando Investment and Tairong Capital.
Transaction Overview
Company Name
Announced On
6/1/2023
Transaction Type
Venture Equity
Amount
$28,229,000
Round
Series C
Proceeds Purpose
The company intends to use the funds to accelerate the clinical development of its core products.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Room 402, Building 5 No. 291 Fucheng Road, Qiantang New Dist
Hangzhou, Zhejiang, Undisclosed
CN
Hangzhou, Zhejiang, Undisclosed
CN
Phone
Website
Email Address
Overview
LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Wan Zhaokui
Chief Operating Officer
Chen Chen
Chief Scientific Officer
Wang Jun
Co-Founder
Michael Vazquez
Browse more venture capital transactions:
Prev: 6/1/2023: Fuse Oncology venture capital transaction
Next: 6/1/2023: UpdateAI venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs